Received May 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | — |
Patient received Twinrix on 4/10/2023, then the patient received a separated HepA and HepB on 10/15/2024; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a patient who received HAB (Hepatitis A and Hepatitis B vaccine) for prophylaxis. Previously administered products included Twinrix (received Twinrix vaccine on 10-APR-2023). On 15-OCT-2024, the patient received Hepatitis A and Hepatitis B vaccine. On 15-OCT-2024, an unknown time after receiving Hepatitis A and Hepatitis B vaccine, the patient experienced drug dose administration interval too long (Verbatim: Patient received Twinrix on 4/10/2023, then the patient received a separated HepA and HepB on 10/15/2024). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 28-APR-2025 The pharmacist reported that a patient received Twinrix on 10th April 2023 and then the patient received a separated HepA and HepB on 15th October 2024 (She did not confirm if it was Havrix and Engerix-B). The reporter reported that and then the patient received Havrix 14th April 2025. The patient received a dose of Hepatitis A and Hepatitis B vaccine later than the recommended interval, which led to lengthening of vaccination schedule. The reporter had a questioned how did they had to proceed, was she considered complete with her doses.